3
Announcements
Trials
Browse
Landscape
Phase
Phase 4
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Prostatic Neoplasms
94
Prostatic Neoplasms, Castration-Resistant
10
Neoplasm Metastasis
8
Breast Neoplasms
8
Neoplasms
7
Triple Negative Breast Neoplasms
4
Metastatic Castration-Resistant Prostate Cancer
4
Carcinoma, Non-Small-Cell Lung
4
Small Cell Lung Carcinoma
3
Parkinson Disease 4, Autosomal Dominant Lewy Body
3
Melanoma
3
Colorectal Neoplasms
3
Carcinoma, Hepatocellular
3
Bulbo-Spinal Atrophy, X-Linked
3
Adenocarcinoma
3
mCRPC
2
Uterine Cervical Neoplasms
2
Squamous Cell Carcinoma of Head and Neck
2
Recurrence
2
Prostate Adenocarcinoma
2
Pancreatic Neoplasms
2
Ovarian Neoplasms
2
Metastatic Hormone-sensitive Prostate Cancer
2
Metastatic Hormone Sensitive Prostate Cancer
2
Metastatic Castration-resistant Prostate Cancer
2
Metastatic Castration-Resistant Prostate Cancer (mCRPC)
2
Bites and Stings
2
Urinary Bladder Neoplasms
1
Stomach Neoplasms
1
Solid Tumor
1
Interventions
enzalutamide
1
bicalutamide
1
Receptors, Androgen
1
Leuprolide
1
Goserelin
1
Flutamide
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Primary Dysautonomias
×
enzalutamide
×
1 year
×
Clear all
NCT05700903
2026-03-02
ARCH
University of Colorado, Denver
Phase 4
Completed
10 enrolled